Once-daily insulin glargine compared with twice-daily nph insulin in patients with type 1 diabetes

Endocrine Practice

Volumn 10, Issue 1, 2004, Pages 10-17

  Hershon, Kenneth S ^a   Blevins, Thomas C ^b   Mayo, Christy A ^c   Rosskamp, Ralf ^d  

^a N Shore Diabet and Endocr Assoc   (United States)

^b Center for Clinical Research   (United States)

^c IQVIA   (United States)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; INSULIN; ISOPHANE INSULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 3242875183     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.10.1.10     Document Type: Article

References (22)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [erratum in Lancet. 1999;354:602]. Lancet. 1998;352:837-853.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [erratum in Lancet. 1998;352:1557]. Lancet. 1998;352:854-865.
4. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28:103-117.
5. Hellman R, Regan J, Rosen H. Effect of intensive treatment of diabetes on the risk of death or renal failure in NIDDM and IDDM. Diabetes Care. 1997;20:258-264.
6. American Diabetes Association. Standards of medical care for patients with diabetes mellitus [erratum in Diabetes Care. 2003;26:972]. Diabetes Care. 2003; 26(Suppl 1):S33-S50.
7. American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr Pract. 2002; 8(Suppl 1):5-11.
8. Cryer PE, Fisher JN, Shamoon H. Hypoglycemia. Diabetes Care. 1994;17:734-755.
9. Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997;46:271-286.
10. Cryer PE. Hypoglycemia unawareness in IDDM. Diabetes Care. 1993;16(Suppl 3):40-47.
11. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and Ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142-2148.
12. Berger M, Cuppers HJ, Hegner H, Jorgens V, Berchtold P. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care. 1982;5:77-91.
13. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23:644-649.
14. Berchtold H, Hilgenfeld R. Binding of phenol to R6 insulin hexamers. Biopolymers. 1999;51:165-172.
15. Hilgenfeld R, Dorschug M, Geisen K, et al. Controlling insulin bioavailability by crystal contact engineering [abstract]. Diabetologia. 1992;35(Suppl 1):A193.
16. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA (U.S. Study Group of Insulin Glargine in Type 1 Diabetes). Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care. 2000;23:639-643.
17. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2000;24:631-636.
18. Rosenstock J, Park G, Zimmerman J (U.S. Insulin Glargine [HOE 901] Type 1 Diabetes Investigator Group). Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care. 2000;23:1137-1142.
19. Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res. 2003;35:189-196.
20. Yki-Jarvinen H, Dressler A, Ziemen M (HOE 901/3002 Study Group). Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000;23:1130-1136.
21. Pieber TR, Eugene-Jolchine I, Derobert E (European Study Group of HOE 901 in Type 1 Diabetes). Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care. 2000;23:157-162.
22. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care. 2000;23:1666-1671.